Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance
One of the biggest, most productive partnerships in antibody development is coming to a close.
Regeneron noted in its Q2 report Thursday that its long …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
